GSK Investigational Site
Kagoshima, 890-0081, Japan
NCT Number: NCT02447393
This is a single center, single blind, single dose, randomized, partial cross-over study to confirm bioequivalence between levocetirizine and cetirizine.
Looking for future studies?
Notify Me20 year–64 year
Male
Interventional
Phase 1
Kagoshima, 890-0081, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AST(GOT), ALT(GPT), total-bilirubin, BUN, creatinine, uric acid,: below the upper normal range
Exclusion criteria
levocetirizine
cetiridine
placebo
Time frame: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose
Area Under the time-concentlation curve
Time frame: predose,0.25,0.5,1,1.5,2,3,4,6,9,12,16,24,36, 48 hours post-dose
maximum concentration
Time frame: predose,1,24 48 hours post-dose
Time frame: predose,24,48 hours post-dose
Time frame: predose,1,24,48 hours post-dose
Time frame: predose,1,24,48 hours post-dose
GlaxoSmithKline
Industry
A Single Blind, Randomized, Single Oral Dose Study to Compare the Oral Disposition of Levocetirizine When Given Alone (5mg) or as the Racemate (Cetirizine 10mg), and to Investigate the Safety and Tolerability and the Pharmacokinetics of Levocetirizine and Cetirizine, Following a Single Dose in Healthy Japanese Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07637695
Dermatitis, Incontinence-associated Dermatitis
Longtan, Taoyuan City, Taiwan
View Trial DetailsNCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial DetailsNCT02558738
Dermatitis, Ear Diseases
Elmshorn, Germany
View Trial DetailsNCT01840605
Atopic, Dermatitis
Hokkaido, Japan
View Trial Details